title: Using discrete choice experiments to investigate subject preferences for preventive asthma medication.
abstract: OBJECTIVE
  Long-term adherence to inhaled corticosteroids is poor despite the crucial role of preventer medications in achieving good asthma outcomes. This study was undertaken to explore patient preferences in relation to their current inhaled corticosteroid medication, a hypothetical preventer or no medication.
  
  
  METHODS
  A discrete choice experiment was conducted in 57 adults with mild-moderate asthma and airway hyper-responsiveness, who were using inhaled corticosteroid <or=500 microg/day (beclomethasone equivalent). In the discrete choice experiment, subjects evaluated 16 hypothetical scenarios made up of 10 attributes that described the process and outcomes of taking asthma medication, with two to four levels for each attribute. For each scenario, subjects chose between the hypothetical medication, the medication they were currently taking and no asthma medication. A random parameter multinomial logit model was estimated to quantify subject preferences for the aspects of taking asthma medication and the influence of attributes on medication decisions.
  
  
  RESULTS
  Subjects consistently made choices in favour of being able to do strenuous and sporting activities with or without reliever, experiencing no side-effects and never having to monitor their peak flow. Frequency of collecting prescriptions, frequency of taking the medication, its route of administration and the strength of the doctor recommendation about the medication were not significant determinants of choice.
  
  
  CONCLUSIONS
  The results of this study suggest that patients prefer a preventer that confers capacity to maximize physical activity, has no side-effects and does not require daily peak flow monitoring.
authors.affiliation: Cooperative Research Centre for Asthma, University of Sydney, Sydney, Australia. emily.lancsar@ncl.ac.uk
authors.forename: Emily J
authors.initials: EJ
authors.lastname: Lancsar
authors.forename: Jane P
authors.initials: JP
authors.lastname: Hall
authors.forename: Madeleine
authors.initials: M
authors.lastname: King
authors.forename: Patricia
authors.initials: P
authors.lastname: Kenny
authors.forename: Jordan J
authors.initials: JJ
authors.lastname: Louviere
authors.forename: Denzil G
authors.initials: DG
authors.lastname: Fiebig
authors.forename: Ishrat
authors.initials: I
authors.lastname: Hossain
authors.forename: Francis C K
authors.initials: FC
authors.lastname: Thien
authors.forename: Helen K
authors.initials: HK
authors.lastname: Reddel
authors.forename: Christine R
authors.initials: CR
authors.lastname: Jenkins
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000368:Aged; D001249:Asthma / Q000453:epidemiology / Q000517:prevention & control*; D001315:Australia / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D017060:Patient Satisfaction; D015995:Prevalence; D011788:Quality of Life; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D005938:Glucocorticoids